HoFH – Homozygous Familial Hypercholesterolemia

Released On
April 14, 2022

Expires On
April 14, 2023

Media Type
Internet

Completion Time
60 minutes

Specialty
Cardiology, Case Management, Critical Care, Endocrinology, Genetics, Geriatric Medicine, Pathology, Pediatrics, Pharmacy, Primary Care

Topic(s)
Acute Coronary Syndrome, Cardiovascular Disease, Diabetes, Heart Disease, Pediatrics, Pharmacology, Stroke

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Horizon CME.

This activity is supported by an independent educational grant from Regeneron.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Contact Hour (0.25 pharmacology hours)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of cardiologists, lipidologists, internists, primary care providers, infusion center nurses, and other healthcare providers who treat patients with FH.

Program Overview

Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder that results in markedly high levels of LDL-C in patients and increased risk of cardiovascular disease and premature mortality. Despite improved understanding of underlying genetic causes and improved strategies for reducing LDL-C, HoFH is still underdiagnosed and undertreated. Because earlier initiation of therapies are associated with improved patient outcomes, it is vital that clinicians diagnose and treat HoFH as soon as possible. However, persistent gaps in clinician identification of HoFH symptoms, lack of awareness of appropriate therapies to use in HoFH patients, and barriers to access to recommended care have resulted in suboptimal treatment of HoFH. Therefore, we propose an activity designed for clinicians who diagnose and treat HoFH patients to close these gaps and improve HoFH patient outcomes and quality of life.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the signs, symptoms, and diagnostic markers of familial hypercholesterolemia
  • Describe current guidelines for the treatment of HoFH
  • Compare and contrast current treatment options for HoFH
  • Formulate care strategies that incorporate patient needs and potential barriers to treatment

Faculty

Moderator

James A. Underberg, MD, MS, FACP, FNLA

Clinical Assistant Professor of Medicine
NYU School of Medicine
NYU Center for Prevention of Cardiovascular Disease

Panelists

Linda Hemphill, MD, FACC, FNLA, FAHA

Instructor in Medicine
Harvard Medical School
Physician, Massachusetts General Hospital

Robert Rosenson, MD Director

Metabolism and Lipids
Mount Sinai Health System
Professor of Medicine (CV Medicine)
Icahn School of Medicine at Mount Sinai

Seth Martin, MD, MHS

Associate Professor of Medicine
Division of Cardiology
Director
Advanced Lipid Disorders Program
Ciccarone Center for the Prevention of Cardiovascular Disease
Johns Hopkins University School of Medicine

Luba Burchett, RN, BSN

Lipid Apheresis Nurse
University of Kansas Health System

Accreditation Statement

Physician Continuing Education
In support of improving patient care, this activity has been planned and implemented by Horizon CME and the Family Heart Foundation. Horizon CME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Nursing Continuing Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME.

Credit Designation

Horizon CME designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 1.0 contact hours and up to 0.25 pharmacology hours.

Disclosures of Conflicts of Interest

In accordance with the ACCME Standards for Commercial Support, Horizon CME must ensure balance, independence, objectivity, and scientific rigor. Prior to an activity, all faculty, authors, editors and planning committee members participating in a Horizon CME activity are required to disclose to attendees any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity. Horizon CME has mitigated any conflicts of interest for this activity.

FACULTY
  • Luba Burchett, RN, BSN, has not had any relevant financial relationships within the past 24 months with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
  • Linda Hemphill, MD, FACC, FNLA, FAHA, has received research support from Novartis and Regeneron during the past 24 months.
  • Seth Martin, MD, has served as on Advisory Boards for Amgen, AstraZeneca, Sanofi, and Novartis during the past 24 months.
  • Robert Rosenson, MD, has served as on Speakers Bureau, Advisory Boards, as Consultant, and received research support from Amgen, Arrowhead, Kowa, Lilly, Novartis, and Regeneron during the past 24 months.
  • James A. Underberg, MD, MS, FACP, FNLA,has served as on Speakers Bureau, Advisory Boards, as Consultant, and received research support from Amarin, Ambry, Amgen, Amryt, Alexion, Esperion, Novartis, Pfizer, and Regeneron during the past 24 months.

The staff of Horizon CME have no relevant financial relationships with ineligible entities.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the post-test.
  4. Complete the evaluation form.

Certificates will be emailed to the participant

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

Horizon CME requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

Disclaimer

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact Information

For CME questions please contact: info@horizon.com